고려대학교 의과대학 및 의과학연구지원센터 구성원이 아닌 경우에는 본인인증을 통하여 글을 작성할 수 있습니다.
- 본인인증 후 글을 작성할 수 있습니다.
내 명의의 휴대전화로 비밀번호를 재설정 할 수 있습니다.
HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors
A research team led by Dr. Tae Woo Kim, a professor of Biochemistry and Molecular biology / Biomedical Science department, Korea University College of Medicine, presents a new target for overcoming resistance to immunotherapy, which may shed new light on potential causes of therapeutic resistance.
Comprehensive pharmacogenomic characterization of gastric cancer
Gastric cancer is among the most lethal human malignancies. Previous studies have identified potential genetic alterations that can be used as therapeutic targets in gastric cancer treatment. However, several challenges prevent clinical success of current targeted therapy. Notably, gastric cancer has multiple genetic alterations, making it difficult to decide which target is the most ideal choice.
Therefore, According to the team’s study led by Professor Jason Kyungha Sa of Cancer genomics / Biomedical Science department, Korea University College of Medicine, we generated patient-derived tumor cell models that have been tested with 60 different anticancer drugs and performed genetic analysis to explore gene-drug associations. Interestingly, we identified tumor-type specific drug sensitivity based on histological, pathological, and genetic classifications. For example, diffuse-type gastric tumors were more sensitive to VEGFR pathway targeting drugs, while signet ring-type gastric tumors were more sensitive to EGFR pathway targeting drugs.
We also found that tumors with ALK mutation could potential be more sensitive to WNT pathway targeting drugs. We also discovered that tumors with PIK3CA mutation, specifically with E542K amino acid change, were significantly more sensitive to AK targeting drug, AZD5363. Lastly, we found that RNF11 gene was significantly associated with drug response to EGFR pathway targeting drug, gefitinib. Collectively, our results show possibility of precision medical treatment through combining high-throughput drug screening with genetic analysis.
A Team Led by Professor Sungeun Kim of Department of Nuclear Medicine Proposed a New Prognosis Predictive Model for Breast Cancer
Investigates Visceral Fat Metabolic Activity and its Correlation with Axillary Lymph Node Metastasis in Postmenopausal Breast Cancer Patients